Clinical investigation of medicinal products in the treatment of Parkinson's disease - Scientific guideline

This document provides guidance on the development for medicinal products for the treatment of Parkinson's disease. Read together with Questions and answers on additional clarification for inclusion criteria in the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease revision 2.

Keywords: Parkinson's disease, Parkinson, confirmatory trials

Current effective version

Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease

AdoptedReference Number: EMA/CHMP/330418/2012 rev. 2

Document history - Revision 2

Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease

AdoptedReference Number: EMA/CHMP/330418/2012 rev. 2

Document history - Revision 1

Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease

AdoptedLegal effective date: 01/02/2009Reference Number: CPMP/EWP/563/95 Rev.1

Overview of comments received on draft guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease

Reference Number: EMEA/402021/2008

Draft guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease

Draft: consultation closedReference Number: CPMP/EWP/563/95 Rev.1

Recommendation on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Alzheimer's disease (CPMP/EWP/553/95) - Revision 1

Reference Number: EMEA/CHMP/EWP/369929/2005